|
|
host
by
zope1
—
last modified
2006-01-16 15:19
|
The VIRGIL-HOST platform aims at understanding and assessing at the
clinical level the host determinant factors involved in virus resistance
to antiviral treatments. Indeed, for understanding the development of
drug resistance it is very important to consider interactions with the
host-cell and organism as well as the immune response. In the case of
resistance or non-responsiveness of HBV, HCV and influenza virus to
antiviral treatment for instance, it is necessary to obtain detailed
insights in the viral modulation of the immune response and the molecular
interactions of viral proteins or viral immune antagonists with the host
cell. The relevance of the host immune response for the permissiveness as
opposed to prevention of antiviral drug resistance is analyzed by the
VIRGIL-HOST platform in a multidisciplinary approach including genetics,
cell biology, clinical/molecular virology, and immunology to understand
the role of host factors in antiviral drug resistance. New techniques and
technical standards are implemented within this platform and the results
of the immunological studies integrated with the genomic and post-genomic
analyses. VIRGIL-HOST benefits from the post-genomic era by taking into
account gene expression profiling analysis for the overall understanding
of the basis of drug resistance development. Establishing such a robust
yet flexible platform helps to address the role of host-cell determinants
in drug resistance development and to design and execute strategies to
control and prevent emergence of resistance for now and in the future. To
that end, VIRGIL-HOST actitivies are organized as follows: |
|
Establishment of a clinical database and sample collection for genetic
studies (in cooperation with VIRGIL-SURVEIL) |
|
Definition of potentially important polymorphisms and establishment of
molecular techniques for rapid analysis of a large number of samples |
|
Establishment and characterisation of transfected
cell lines for the study of protein-protein interaction and alterations in
virus-induced cellular signalling |
|
Sample collection (serum and PBMC) of relevant
groups of patients for immunological studies |
|
Establishment of new techniques for the
characterisation of dendritic cell subsets |
|
Establishment of new techniques for the
characterisation of virus specific T cells |
|
Understanding the emergence of influenza virus
resistant variants to amantadine and neuraminidase inhibitors on the level
of and the immune response |
|
Investigation of drug resistance development and the
mode of action of novel and upcoming drugs |
|
Definition of groups of patients at risk for
development of viral resistance during antiviral therapy. |
 |
|
|
«
|
January
2009
|
»
|
| Su |
Mo |
Tu |
We |
Th |
Fr |
Sa |
|
|
|
|
1 |
2 |
3 |
| 4 |
5 |
6 |
7 |
8 |
9 |
10 |
| 11 |
12 |
13 |
14 |
15 |
16 |
17 |
| 18 |
19 |
20 |
21 |
22 |
23 |
24 |
| 25 |
26 |
27 |
28 |
29 |
30 |
31 |
|
Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe